Upload
creola
View
29
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Changing the criteria for Alzheimer ’ s disease Alzheimer Europe - Vienna, October 2012 . Pr Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital – Paris 6 University . DISCLOSURE. - PowerPoint PPT Presentation
Citation preview
Changing the criteria forAlzheimer’s disease
Alzheimer Europe - Vienna, October 2012
Pr Bruno DuboisHead of the Dementia Research Center (IMMA)
Director of INSERM Research Unit (ICM)Salpêtrière Hospital – Paris 6 University
DISCLOSURE
1) Reimbursed travels for speaking engagements, congress participation or educational activities: Eisai, Janssen-Cilag, Novartis
2) Consultancy: Affiris, BMS, Eli Lilly, Pfizer, Roche
3) Funding for my Institution: Novartis, Roche
The NINCDS-ADRDA criteria
neuropathology
CLINICAL
POST-MORTEM
MCI dementia
probable/possible AD[
1) The diagnosis of AD is clinico-pathological: it cannot be certified clinically and needs a post-mortem confirmation to be ascertained
2) The diagnosis of AD can only be ‘probable’ 3) The diagnosis of AD can only be made when the disease is
advanced and reaches the threshold of dementia
1984The rules
The current NINCDS-ADRDA diagnostic criteria have several limitations
Two requirements:1) to be earlier2) to be more
specific
A low accuracy (60 to 80%) because they do not take into account the specific features of the disease
Late in the course of the disease only when the dementia threshold is reached !
To be earlier: potential benefits
• Obtain appropriate treatment earlier• Stop searching for other causes• Help the family to understand and accept• Financial and legal plans while competent• Enable the patient and family to make lifestyle choices• Induce better adherence and management of other medical conditions• Take appropriate steps to prevent injury (driving, weapons)• Get greater access to help within the healthcare system • Participate in clinical trials with disease modifier treatments
from Cummings, 2011
To be earlier
Preclinical states
Current point of
diagnosis
3–5 yrs
Specific memory disorders
Dementia
First symptoms
Biomarkers
AD?AD?AD?
What is Alzheimer’s disease?
DrugsMCI Subcortical
dementia
Depression
Normal aging
FTDAD
Vascular disorders
Confusion
Low free recall
Sleep disorders
AD is a progressive amnestic disease
In more than 85% of the cases, AD starts as a progressive amnesic disease in relation with an early involvement of the hippocampus
The Different Stages of LT MemoryThe Different Stages of LT Memory
Temporal lobe (AD)
StorageRegistration Retrieval
Stimulus Stimulus
Control of encoding with cueing1
Facilitate the retrieval with cueing2
Frontal lobe (aging)
Attention
(depression)
Dubois and Albert, Lancet Neurology, 2004
FCSRT (cued recall measures) is the best predictor of AD
pathology
memory measures CSF (+)n = 74
CSF (–)n = 111
effect size (d)
FCSRT Total Recall 13.4 15.4 0.97
Logical Memory Delayed Recall 8.12 13.59 0.74
CERAD verbal Delayed recall 4.22 5.63 0.71
Wagner M et al, Neurology 2012
AD: can the exam predict the pathology?
• PET-PiB. PET-PiB. Increased radio-ligand Increased radio-ligand retention in AD retention in AD compared to compared to control subjects control subjects ((Klunk, Klunk, 20042004))
• PET-FDG.PET-FDG. Pooled Pooled sensitivities and sensitivities and specificities (9 specificities (9 studies) of 86% for studies) of 86% for temporo-parietal temporo-parietal hypometabolismhypometabolism ((Patwardhan, 2004Patwardhan, 2004))
PET imaging
A specific pattern in Molecular A specific pattern in Molecular Neuroimagery Neuroimagery (Klunk et al., 2004)
(Hansson et al. LN, 2006)
1.0
0.8
0.6
0.4
0.2
0
No p
rogr
essio
n to
AD
0 10 20 30 40 50 60 Time (months)
Normal CSFPathological
CSF (low A beta, high tau/p-
tau)
Normal CSF 67 66 62 56 47 40 28Pathological CSF 67 65 49 31 27 15 3
specific pattern of CSF changes (low A beta; high tau and P-tau levels) even at an eary stage
Being more specific even at the prodromal
stage of AD
memory CSF MRI PET-FDG PET-ligand
NINCDS - ADRDA
not specified exclusion exclusion not specified not known
IWG criteria
amnestic ε H type
Abeta T- P tau
MTL atrophy P–T hypo metabolism
PiB retention
Specificity for Prodromal
AD
>90% Sarazin
2007
>90% Hanson
2006
>85% Colliot 2008
>80% Mosconi
2004
>95% Rowe 2007
Sarazin et al. Neurology. 2007;69:1859-2016. Hansson et al. Lancet Neurol. 2006;5:228–234. Colliot et al. Psychiatr Sci Hum Neurosci. 2008;6:68-75. Mosconi et al. Neurology. 2004;63:2332-2340. Rowe et al. Alzheimers Dement. 2007;3.
Structural: atrophy of medial temporal lobe (MRI)Biological: changes in biomarkers (CSF)Metabolic neuroimaging: regional hypometabolism on PETMolecular neuroimaging: amyloid ligand retention on PET
Amnestic syndrome of the ‘hippocampal type’ (that can be isolated or associated to other cognitive / behavioral changes)
1 major clinical criterion
+ 1 or more biomarker present
Dubois et al., Lancet Neurol., 2007
Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria
Before 20071) dementia: loss of autonomy2) elimination of other causes of dementia:
blood exams : endocrinopathies, infectious or inflammatory disorders… CT-Scan/MRI : vascular lesions, tumor, hydrocephalus…Diagnosis based on an exclusionary process
Since 2007 1) an amnestic syndrome of the hippocampal type2) integration of biomarkers in the diagnostic process:
a biological signature on CSF the visualisation of brain lesions with PET amyloid tracer Diagnosis based on positive arguments
New Diagnostic approach
neuropathology
CLINICAL
POST-MORTEM
MCI dementiaprobable/possible
Biomarkers
CLINICAL
BIOLOGICAL
typical / atypical
[
[alzheimer’s disease
alzheimer’s disease
The conceptual shift
1984NINCDS-ADRDA
2007 IWG
clinical pathological entity
clinical biological entity
1) In research settings: A high diagnostic accuracy is needed for:• study of specific outcomes: requires well phenotyped cohorts• academic research projects: not on heterogeneous population with a
low/intermediate likelihood of diagnostic accuracy• inclusion in clinical trials : most of ongoing trials are based on the New
Criteria: BMS (γ secretase inhibitor); Affiris (immunotherapy): Roche (immunotherapy); Lilly (BACE inhibitor); Nutricia (Medical food-Souvenaid); Sanofi (immunotherapy) …
2) In specific clinical conditions: BMs increase diagnostic accuracy that may be required in case of:
• young onset AD• complex cases: PCA, PPA…
Applicability of the New Criteria: When?
The new lexicon1) AD: starts with the first specific symptoms and encompasses both the prodromal and dementia phases2) AD dementia: phase of AD with an impact on ADL3) Prodromal AD: the early symptomatic, predementia phase of AD4) Typical AD: common clinical phenotype of AD, characterized by an early amnestic syndrome of the hippocampal type5) Atypical AD: less common but well characterized clinical phenotypes logopenic aphasia, posterior cortical atrophy, frontal variant of AD The diagnosis of AD needs in vivo evidence of pathophysiological markers6) Mixed AD: patients who fulfill the criteria for AD with clinical and biomarkers evidence of other co-morbid disorders7) Asymptomatic at risk: cognitively normal individuals with in vivo pathophysiological biomarkers of AD8) Presymptomatic AD: cognitively normal individuals with a proven autosomal dominant mutation9) Alzheimer’s pathology: neurobiological changes responsible for AD10) MCI: patients for whom there is no disease clearly identified
(Dubois et al, Lancet Neurology 2010)